文献速递白血病MDS 与骨髓增殖性肿瘤

急性髓系白血病患者中SRSF2、U2AF1和SF3B1突变的临床表现与差异剪接

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia.
PubMed 文献 · Leukemia · 2020-05-01

研究对2678例急性髓系白血病患者分析剪接因子突变,发现SRSF2、U2AF1、SF3B1突变者无复发生存和总生存较差,但并非独立预后标志。对246例RNA测序并在177例独立验证,发现每种突变有高度特征性异构体表达谱,并检出大量新差异剪接位点。

要点

  • 剪接因子突变与较差的无复发生存和总生存相关,但非独立预后标志。
  • 每种剪接因子突变具有高度特征性的异构体表达谱,多个异构体明显失调。
  • SRSF2(P95H)突变体中两个过度使用的剪接位点对总生存的影响得到验证。

核心结论

  • 剪接因子突变不是独立预后标志,但全基因组影响基因剪接,导致多个基因异构体表达失调。

研究设计与样本

  • 对2678例患者进行临床分析;对246例进行RNA测序,并在177例中独立验证;建立定制差异剪接位点使用流程检测异常剪接。

主要发现

  • 剪接因子突变者无复发生存和总生存较差,但这些突变不是独立预后标志。
  • 246例RNA测序和177例独立验证显示,每种突变具有高度特征性的异构体表达谱,多个异构体明显失调。
  • 定制流程准确检测到剪接因子突变样本中的异常剪接,大部分差异使用位点为新发现,包括白血病相关基因中的若干位点。
  • 在SRSF2(P95H)突变体中探索了剪接通路失调的级联效应可能性。
  • SRSF2(P95H)突变体中两个过度使用的剪接位点对总生存的影响得到验证。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous studies demonstrated that splicing factor mutations are recurrent events in hematopoietic malignancies with both clinical and functional implications. However, their aberrant splicing patterns in acute myeloid leukemia remain largely unexplored. In this study, we characterized mutations in SRSF2, U2AF1, and SF3B1, the most commonly mutated splicing factors. In our clinical analysis of 2678 patients, splicing factor mutations showed inferior relapse-free and overall survival, however, these mutations did not represent independent prognostic markers. RNA-sequencing of 246 and independent validation in 177 patients revealed an isoform expression profile which is highly characteristic for each individual mutation, with several isoforms showing a strong dysregulation. By establishing a custom differential splice junction usage pipeline, we accurately detected aberrant splicing in splicing factor mutated samples. A large proportion of differentially used junctions were novel, including several junctions in leukemia-associated genes. In SRSF2(P95H) mutants, we further explored the possibility of a cascading effect through the dysregulation of the splicing pathway. Furthermore, we observed a validated impact on overall survival for two junctions overused in SRSF2(P95H) mutants. We conclude that splicing factor mutations do not represent independent prognostic markers. However, they do have genome-wide consequences on gene splicing leading to dysregulated isoform expression of several genes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bamopoulos SA, Batcha AMN, Jurinovic V, et al. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia. 2020. PMID: 32358566. doi:10.1038/s41375-020-0839-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。